Randomized trial of megestrol acetate vs. megestrol acetate/tamoxifen for the management of progressive or recurrent epithelial ovarian carcinoma

Gynecol Oncol. 1987 Oct;28(2):151-5. doi: 10.1016/0090-8258(87)90208-3.

Abstract

Thirty-three patients were randomly treated with either megestrol acetate (Mg) or megestrol acetate/tamoxifen (Mg/Tx) from November, 1983, to December, 1985. Thirty-two of 33 were previously treated with platinum-based combination chemotherapy. Ten of 32 were also treated with hexamethylmelamine-based second line therapy. Doses were 160 mg/day of Mg and 20 mg/day of Tx. All patients had measurable disease. The two groups did not differ as to progression-free interval. There were no patients who demonstrated tumor regression. Overall, 39% showed stabilization of disease from 4 to 16+ months (median 8.0 months and mean 9.0 months).

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Carcinoma / drug therapy*
  • Clinical Trials as Topic
  • Female
  • Humans
  • Megestrol / administration & dosage
  • Megestrol / analogs & derivatives*
  • Megestrol Acetate
  • Middle Aged
  • Neoplasm Recurrence, Local / drug therapy
  • Ovarian Neoplasms / drug therapy*
  • Random Allocation
  • Tamoxifen / administration & dosage*

Substances

  • Tamoxifen
  • Megestrol
  • Megestrol Acetate